In trading on Thursday, shares of Westport Innovations, Inc.entered into oversold territory, hitting an RSI reading of 28.9, after changing hands as low as $12.71 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 58.2. A bullish investor could look at WPRT’s 28.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Westport Innovations Inc. (USA) (NASDAQ:WPRT)stock performance was 24.28% in last session and finished the day at $ 16.07. Traded volume was 7.14 million shares in the last session and the average volume of the stock remained 941,731.00 shares. The beta of the stock remained 1.46. Westport Innovations Inc. (USA) (NASDAQ:WPRT)insider ownership is 17.71%
Pharmacyclics Incorporated (Nasdaq:PCYC)’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and expanding profit margins. However, as a counter to these strengths, there are also found weaknesses including unimpressive growth in net income, weak operating cash flow and feeble growth in the company’s earnings per share. Pharmacyclics, Inc. (NASDAQ:PCYC) dropped -7.44% percent to $ 4.81M yesterday on volume of 88.13 million shares. The intra-day range of the stock was $84.00 – 93.00. Pharmacyclics, Inc. (NASDAQ:PCYC)has a market capitalization of $ 6.61 billion.
QLogic Corp. (NASDAQ:QLGC) last released its earnings data on Thursday, May 1st. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.02. QLogic Corporation (NASDAQ:QLGC)’s stock on May 2, 2014 reported a decrease of -7.91% to the closing price of $ 9.90. Its fifty two weeks range is $9.29 – 13.06. The total market capitalization recorded $ 860.86 million . The overall volume in the last trading session was 4.37 million shares. In its share capital, QLogic Corporation(NASDAQ:QLGC) has 86.96 million outstanding shares.
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) together with its subsidiaries, is engaged in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. Currently there are 3 analysts that rate AVANIR Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold. On Friday, shares of Avanir Pharmaceuticals Inc (NASDAQ:AVNR) dropped -0.43% to close the day at $ 4.63. Company return on investment (ROI) is -149.40% and its monthly performance is recorded as 22.16% Avanir Pharmaceuticals Inc (NASDAQ:AVNR) quarterly revenue growth is 23.47%.